NIAID-DVI: Sanofi CYD dengue vaccine--Where do we go from here? Jean Lang and Bruno Guy

Blog Series: NIAID-DVI

Sanofi Pasteur CYD dengue vaccine programme update

Jean Lang
Sanofi Pasteur

and

Immunological characterization of the Sanofi Pasteur dengue vaccine candidate: hypotheses and investigations to explain results of the Phase IIb proof of concept efficacy trial in Ratchaburi
Bruno Guy
Sanofi Pasteur

So by way of quick review:

credit: Roehrig's Presentation

• the CYD-TDV vaccine is a yellow fever backbone with the prM and E genes replaced by each of the dengue serotypes.
• There was good response in efficacy trials to dengue 1, 3 and 4 however the vaccine failed in illiciting a response to dengue 2 (response was about 30%) DESPITE having satsifactory PRNT titers...see previous blog post.
• In 2012 there was a Phase IIb efficacy trial in Ratchaburi, Thailand
• It showed the vaccine was safe.
• It showed that it was possible to make an efficacious vaccine against dengue
• It raised questions on the reference PRNT assay
• It challenged some of the dengue vaccine development hypotheses
• It reminds us how complex the disease is